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the impact of the disease on life expectancy. As an exam-
ple of the application of our method, we have reanalyzed
a survival data set reported by Spinolo et al. (1992) that
refers to patients with acute leukemia who relapsed after
their first allogeneic bone marrow transplant (BMT). We
obtained the following results: total AUC leukemia pa-
tients (normalized to 100 patients)  10,590 months,
mean lifetime survival per patient (MLS)  105.9 months
or 8.8 years; total AUC healthy subjects  58,376
months, MLS  583.8 months or 48.6 years. These data
indicate that the average life expectancy (or MLS) after a
second BMT was 8.8 years compared with 48.6 years in
an age-matched and gender-matched cohort of healthy
subjects. Our survival analysis shows that, in this very se-
rious disease condition, the absolute reduction in life ex-
pectancy was 39.8 years per patient and the percent re-
duction was 82%.
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PRACTICE PATTERNS OF CHEMOTHERAPY 
USAGE AND ASSOCIATED NEUTROPENIA AND 
FEBRILE NEUTROPENIA (FN) IN EUROPE
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Neutropenia and associated FN are major dose-limiting
toxicities of cancer chemotherapy and impact consider-
ably on the costs of care and patient quality of life. There
is little information available concerning patterns of che-
motherapy treatment and their associated complications
in Europe.
OBJECTIVES: To study patterns of chemotherapy usage
and the occurrence of neutropenia and FN in cancer pa-
tients in Europe.
METHODS: Recent patterns of cancer treatment were
examined from survey data provided by ISIS Research
for the five major European economic markets ($bn
GDP): Germany (2115), France (1394), United Kingdom
(1278), Italy (1146), and Spain (533). Data were evalu-
ated from 60 cancer specialists and 1200 cancer patients
receiving cancer treatment in each country. Practice pat-
terns examined included the use of systemic chemother-
apy, the occurrence of neutropenia and FN and the type
of supportive care provided.
RESULTS: Ninety percent of patients were receiving
treatment with chemotherapy, of which 20% was admin-
istered in an adjuvant fashion. Average patient age was
55 years and 53% were female. Major treated cancers in-
cluded those of breast (23%), colon (13%), and lung
(12%). Approximately one-half of patients were newly
diagnosed, while 25% were described as heavily pre-
tested. Nearly 40% of patients had experienced a prior
episode of severe neutropenia and 10% had experienced
a previous infection. Concurrent use of colony-stimulat-
ing factors (CSFs) was reported in 15% of patients. Ma-
jor factors predicting CSF use included previous or antici-
pated severe neutropenia, FN, or infection. Considerable
regional variation was evident in the treatment practices
observed.
CONCLUSIONS: Neutropenia and FN are frequent com-
plications of systemic cancer chemotherapy in Europe.
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There are few long-term data about Parkinson’s disease
(PD) other than from hospital clinics, which may see a bi-
ased selection of patients.
 
METHODS:
 
 We used two populations in Tayside: one
with complete prescribing data from 1989–1995 (n 
30,000) and the second with data from 1985–1995 (n 
10,000). The first 6 months of data were used to identify
incident cases and to exclude those who had previously
taken a neuroleptic drug. Cases were matched for age,
sex, and general practice to nine controls.
RESULTS: The number of cases of incident PD was 108
in the 7-year cohort and 28 in the 11-year cohort. In the
7-year cohort, patients were aged 45–95 (median 76.0),
and 55% were male. The most commonly prescribed
drug was co-beneldopa at a mean dose of 187 mg. In
comparison with control, PD patients were significantly
more likely to receive additional drugs for gastrointesti-
nal (relative risk [RR] 2.0; 95% confidence interval [CI]
1.4–3.3) and cardiovascular (RR 1.7; CI 1.2–2.4) disor-
ders. Median costs of hospitalization were higher in PD
(14,119 vs. 5,077; p  0.0001) because of increased
numbers of episodes per patient and costs per episode
(1,965 vs. 1,526; p  0.002). Relative risk of mortality in
PD patients was very similar in the 7-year cohort (RR 
2.50, CI 1.74–3.57) and the 11-year cohort (RR  2.25,
CI 1.43–3.54).
CONCLUSIONS: This population-based study provides
an unbiased estimate of the costs and mortality of PD,
hence of the potential value of improved treatment.
